CCS Researchers of the Hartmann Lab Contribute to the Identification of a Loophole in Chronic Lymphocytic Leukemia Treatment

January 9, 2018

A team of medical researchers including the Hartmann CCS lab

have determined that a drug approved to treat chronic lymphocytic leukemia (CLL) may be less effective in a particular subset of patients. The study, which has been published in the latest issue of the Journal of Experimental Medicine, reveals that ibrutinib has a diminished capacity to delocalize and kill tumor cells expressing an adhesive protein called CD49d, but combining ibrutinib treatment with drugs that block CD49d activation could prevent the tumor cells from sheltering in lymphoid organs. Klick here for more details.

Please reload

 Recommended News 

Salzburg Breast Cancer Meeting - Mastering Translational Immuno-Oncology

January 13, 2017

Please reload

 Recent News 
Please reload